Reduced HMGB 1-Mediated Pathway and Oxidative Stress in Resveratrol-Treated Diabetic Mice: A Possible Mechanism of Cardioprotection of Resveratrol in Diabetes Mellitus

Oxidative Medicine and Cellular Longevity

Volumn 2016, Issue , 2016, Pages

  Wu, Han ^a   Sheng, Zhen Qiang ^b,c   Xie, Jun ^a   Li, Ran ^a   Chen, Liang ^b,c   Li, Guan Nan ^a   Wang, Lian ^a   Xu, Biao ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c NANTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BODY FLUIDS; ELECTROPHORESIS; MAMMALS; OXIDATIVE STRESS; PATHOLOGY; SIGNALING;

ANTI-INFLAMMATORIES; ANTIFIBROTIC EFFECT; DIABETIC CARDIOMYOPATHY; HIGH-MOBILITY GROUPS; MYOCARDIAL FIBROSIS; POSSIBLE MECHANISMS; PROINFLAMMATORY CYTOKINES; WESTERN-BLOT ANALYSIS;

RESVERATROL;

ADVANCED GLYCATION END PRODUCT RECEPTOR; GLUCOSE; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P47; PROTEIN P66; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; RESVERATROL; TOLL LIKE RECEPTOR 4; CYBB PROTEIN, MOUSE; GLUCOSE BLOOD LEVEL; MEMBRANE PROTEIN; NEUTROPHIL CYTOSOLIC FACTOR 1; PROTECTIVE AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SHC TRANSFORMING PROTEIN 1; SHC1 PROTEIN, MOUSE; STILBENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDITIS; CONTROLLED STUDY; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HEART; HEART MUSCLE FIBROSIS; HEART PROTECTION; LOW DRUG DOSE; MALE; MONOCYTE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SYSTEMATIC REVIEW; WESTERN BLOTTING; ANALYSIS; ANIMAL; BLOOD; BODY WEIGHT; CHEMICALLY INDUCED; CYTOLOGY; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; DOWN REGULATION; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROSIS; INFLAMMATION; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROSIS; HEART; HMGB1 PROTEIN; INFLAMMATION; MALE; MEMBRANE GLYCOPROTEINS; MICE; MONOCYTES; NADPH OXIDASE; OXIDATIVE STRESS; PROTECTIVE AGENTS; SIGNAL TRANSDUCTION; SRC HOMOLOGY 2 DOMAIN-CONTAINING, TRANSFORMING PROTEIN 1; STILBENES;

EID: 84994391746     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2016/9836860     Document Type: Article

References (51)

1. IDF Diabetes Atlas Group, "Update of mortality attributable to diabetes for the IDF Diabetes Atlas: estimates for the year 2013," Diabetes Research and Clinical Practice, vol. 109, no. 3, pp. 461-465, 2015.
2. G. Danaei, C. M. Lawes, S. Vander Hoorn, C. J. Murray, and M. Ezzati, "Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment," The Lancet, vol. 368, no. 9548, pp. 1651-1659, 2006.
3. S. Boudina and E.D. Abel, "Diabetic cardiomyopathy revisited," Circulation, vol. 115, no. 25, pp. 3213-3223, 2007.
4. M. Galderisi, K. M. Anderson, P. W. F. Wilson, and D. Levy, "Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (The Framingham Heart Study)," The American Journal of Cardiology, vol. 68, no. 1, pp. 85-89, 1991.
5. O. Lorenzo, B. Picatoste, S. Ares-Carrasco, E. Ramírez, J. Egido, and J. Tuñón, "Potential role of nuclear factor κb in diabetic cardiomyopathy," Mediators of Inflammation, vol. 2011, Article ID 652097, 9 pages, 2011.
6. H. Wu, G.-N. Li, J. Xie et al., "Resveratrol ameliorates myocardial fibrosis by inhibiting ROS/ERK/TGF-β/periostin pathway in STZ-induced diabetic mice," BMC Cardiovascular Disorders, vol. 16, no. 1, article 5, 2016.
7. M. Mohammadshahi, F. Haidari, and F. G. Soufi, "Chronic resveratrol administration improves diabetic cardiomyopathy in part by reducing oxidative stress," Cardiology Journal, vol. 21, no. 1, pp. 39-46, 2014.
8. M.-S. Beaudoin, C. G. R. Perry, A. M. Arkell et al., "Impairments in mitochondrial palmitoyl-CoA respiratory kinetics that precede development of diabetic cardiomyopathy are prevented by resveratrol in ZDF rats," Journal of Physiology, vol. 592, no. 12, pp. 2519-2533, 2014.
9. M. Sulaiman, M. J. Matta, N. R. Sunderesan, M. P. Gupta, M. Periasamy, and M. Gupta, "Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy," American Journal of Physiology-Heart and Circulatory Physiology, vol. 298, no. 3, pp. H833-H843, 2010.
10. F. Delucchi, R. Berni, C. Frati et al., "Resveratrol treatment reduces cardiac progenitor cell dysfunction and prevents morpho-functional ventricular remodeling in type-1 diabetic rats," PLoS ONE, vol. 7, no. 6, Article ID e39836, 2012.
11. H. Yang and K. J. Tracey, "Targeting HMGB1 in inflammation," Biochimica et Biophysica Acta-Gene Regulatory Mechanisms, vol. 1799, no. 1-2, pp. 149-156, 2010.
12. H. C. Volz, C. Seidel, D. Laohachewin et al., "HMGB1: the missing link between diabetes mellitus and heart failure," Basic Research in Cardiology, vol. 105, no. 6, pp. 805-820, 2010.
13. D. Yao and M. Brownlee, "Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands," Diabetes, vol. 59, no. 1, pp. 249-255, 2010.
14. X. Ye, M. Chopp, X. Liu et al., "Niaspan reduces high-mobility group box 1/receptor for advanced glycation endproducts after stroke in type-1 diabetic rats," Neuroscience, vol. 190, pp. 339-345, 2011.
15. L. J. Wang, L. Lu, F. R. Zhang, Q. J. Chen, R. De Caterina, and W. F. Shen, "Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure," European Journal of Heart Failure, vol. 13, no. 4, pp. 440-449, 2011.
16. W.-K. Wang, B. Wang, Q.-H. Lu et al., "Inhibition of highmobility group box 1 improves myocardial fibrosis and dysfunction in diabetic cardiomyopathy," International Journal of Cardiology, vol. 172, no. 1, pp. 202-212, 2014.
17. M. He, H. Kubo, K. Ishizawa et al., "The role of the receptor for advanced glycation end-products in lung fibrosis," American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 293, no. 6, pp. L1427-L1436, 2007.
18. C.-T. Tu, Q.-Y. Yao, B.-L. Xu, J.-Y. Wang, C.-H. Zhou, and S.-C. Zhang, "Protective effects of curcumin against hepatic fibrosis induced by carbon tetrachloride: modulation of high-mobility group box 1, Toll-like receptor 4 and 2 expression," Food and Chemical Toxicology, vol. 50, no. 9, pp. 3343-3351, 2012.
19. M. Entezari, D. J. Weiss, R. Sitapara et al., "Inhibition of highmobility group box 1 protein (HMGB1) enhances bacterial clearance and protects against Pseudomonas aeruginosa pneumonia in cystic fibrosis," Molecular Medicine, vol. 18, no. 1, pp. 477-485, 2012.
20. 2+/calmodulin-dependent protein kinase II activity in diabetic mouse retina," Diabetes, vol. 59, no. 7, pp. 1825-1835, 2010.
21. H. Zhang, B. Morgan, B. J. Potter et al., "Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress: in vivo demonstration with magnetic resonance imaging," American Journal of Physiology-Heart and Circulatory Physiology, vol. 299, no. 4, pp. H985-H994, 2010.
22. H. Wu, R. Li, Z.-H. Wei et al., "Diabetes-induced oxidative stress in endothelial progenitor cells may be sustained by a positive feedback loop involving high mobility group box-1," Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 1943918, 9 pages, 2016.
23. J. Kim, E. Sohn, C.-S. Kim, K. Jo, and J. S. Kim, "The role of highmobility group box-1 protein in the development of diabetic nephropathy," American Journal of Nephrology, vol. 33, no. 6, pp. 524-529, 2011.
24. A. Soro-Paavonen, A. M. D. Watson, J. Li et al., "Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes," Diabetes, vol. 57, no. 9, pp. 2461-2469, 2008.
25. Y. Yang, S. Li, Q. Yang et al., "Resveratrol reduces the proinflammatory effects and lipopolysaccharide-induced expression of HMGB1 and TLR4 in RAW264.7 cells," Cellular Physiology and Biochemistry, vol. 33, no. 5, pp. 1283-1292, 2014.
26. E. de Cillis, A. Leonardini, L. Laviola, F. Giorgino, L. D. L. Tupputi Schinosa, and A. S. Bortone, "Different gene expression in human heart tissue and progenitor cells from control and diabetic subjects: relevance to the pathogenesis of human diabetic cardiomyopathy," Surgical Technology International, vol. 19, pp. 165-174, 2010.
27. D. Tang, Y. Shi, R. Kang et al., "Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1," Journal of Leukocyte Biology, vol. 81, no. 3, pp. 741-747, 2007.
28. J. Fan, Y. Li, R. M. Levy et al., "Hemorrhagic shock induces NAD(P)H oxidase activation in neutrophils: role of HMGB1-TLR4 signaling," Journal of Immunology, vol. 178, no. 10, pp. 6573-6580, 2007.
29. M. M. Rabadi, T. Ghaly, M. S. Goligorksy, and B. B. Ratliff, "HMGB1 in renal ischemic injury," American Journal of Physiology-Renal Physiology, vol. 303, no. 6, pp. F873-F885, 2012.
30. E. Marcolin, B. San-Miguel, D. Vallejo et al., "Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis," Journal of Nutrition, vol. 142, no. 10, pp. 1821-1828, 2012.
31. T.-W. Lee, Y.-H. Kao, T.-I. Lee, C.-J. Chang, G.-S. Lien, and Y.-J. Chen, "Calcitriol modulates receptor for advanced glycation end products (RAGE) in diabetic hearts," International Journal of Cardiology, vol. 173, no. 2, pp. 236-241, 2014.
32. M. Rajesh, S. Bátkai, M. Kechrid et al., "Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy," Diabetes, vol. 61, no. 3, pp. 716-727, 2012.
33. Y. Zhang, T. Peng, H. Zhu et al., "Prevention of hyperglycemiainduced myocardial apoptosis by gene silencing of Toll-like receptor-4," Journal of Translational Medicine, vol. 8, article 133, 2010.
34. Z.-W. Liu, J.-K. Wang, C. Qiu et al., "Matrine Pretreatment improves cardiac function in rats with diabetic cardiomyopathy via suppressing ROS/TLR-4 signaling pathway," Acta Pharmacologica Sinica, vol. 36, no. 3, pp. 323-333, 2015.
35. Y.-H. Jing, K.-H. Chen, S.-H. Yang, P.-C. Kuo, and J.-K. Chen, "Resveratrol ameliorates vasculopathy in STZ-induced diabetic rats: role of AGE-RAGE signalling," Diabetes/Metabolism Research and Reviews, vol. 26, no. 3, pp. 212-222, 2010.
36. H. S. Youn, J. Y. Lee, K. A. Fitzgerald, H. A. Young, S. Akira, and D. H. Hwang, "Specific inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: molecular targets are TBK1 and RIP1 in TRIF complex," The Journal of Immunology, vol. 175, no. 5, pp. 3339-3346, 2005.
37. A. Bugyei-Twum, A. Advani, S. L. Advani et al., "High glucose induces Smad activation via the transcriptional coregulator p300 and contributes to cardiac fibrosis and hypertrophy," Cardiovascular Diabetology, vol. 13, article 89, 2014.
38. Z. Su, J. Yin, T. Wang et al., "Up-regulated HMGB1 in EAM directly led to collagen deposition by a PKCβ/Erk1/2-dependent pathway: cardiac fibroblast/myofibroblast might be another source of HMGB1," Journal of Cellular and Molecular Medicine, vol. 18, no. 9, pp. 1740-1751, 2014.
39. W. Zhang, K. J. Lavine, S. Epelman et al., "Necrotic myocardial cells release damage-associatedmolecular patterns that provoke fibroblast activation in vitro and trigger myocardial inflammation and fibrosis in vivo," Journal of the American Heart Association, vol. 4, no. 6, Article ID e001993, 2015.
40. M. Andrassy, H. C. Volz, J. C. Igwe et al., "High-mobility group box-1 in ischemia-reperfusion injury of the heart," Circulation, vol. 117, no. 25, pp. 3216-3226, 2008.
41. -/- mice by downregulating the HMGB1-RAGE axis," Acta Pharmacologica Sinica, vol. 34, no. 6, pp. 830-836, 2013.
42. R. Ramasamy, S. F. Yan, and A. M. Schmidt, "Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications," Annals of the New York Academy of Sciences, vol. 1243, no. 1, pp. 88-102, 2011.
43. H. C. Volz, Z. Kaya, H. A. Katus, and M. Andrassy, "The role of HMGB1/RAGE in inflammatory cardiomyopathy," Seminars in Thrombosis and Hemostasis, vol. 36, no. 2, pp. 185-194, 2010.
44. X. Tao, X. Sun, L. Yin et al., "Dioscin ameliorates cerebral ischemia/reperfusion injury through the downregulation of TLR4 signaling via HMGB-1 inhibition," Free Radical Biology and Medicine, vol. 84, Article ID 12343, pp. 103-115, 2015.
45. H. Mudaliar, C. Pollock, J. Ma, H. Wu, S. Chadban, and U. Panchapakesan, "The role of TLR2 and 4-mediated inflammatory pathways in endothelial cells exposed to high glucose," PLoS ONE, vol. 9, no. 10, article e108844, 2014.
46. P. B. Jakus, N. Kalman, C. Antus et al., "TRAF6 is functional in inhibition of TLR4-mediated NF-κB activation by resveratrol," Journal of Nutritional Biochemistry, vol. 24, no. 5, pp. 819-823, 2013.
47. H. Ghanim, C. L. Sia, K. Korzeniewski et al., "A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal," The Journal of Clinical Endocrinology & Metabolism, vol. 96, no. 5, pp. 1409-1414, 2011.
48. O. Prabhakar, "Cerebroprotective effect of resveratrol through antioxidant and anti-inflammatory effects in diabetic rats," Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 386, no. 8, pp. 705-710, 2013.
49. Y. Gao, L. Kang, C. Li et al., "Resveratrol ameliorates diabetesinduced cardiac dysfunction through AT1R-ERK/p38 MAPK signaling pathway," Cardiovascular Toxicology, vol. 16, no. 2, pp. 130-137, 2016.
50. G. Chen, J. Li, M. Ochani et al., "Bacterial endotoxin stimulates macrophages to release HMGB1 partly through CD14-and TNF-dependentmechanisms," Journal of Leukocyte Biology, vol. 76, no. 5, pp. 994-1001, 2004.
51. R. Kang, R. Chen, Q. Zhang et al., "HMGB1 in health and disease," Molecular Aspects of Medicine, vol. 40, pp. 1-116, 1998.